Digital health company Noom is stepping into the weight loss drug market with a new offering aimed at providing a more affordable solution for consumers. On Thursday, Noom announced it will introduce a weight loss product featuring compounded semaglutide, the same active ingredient found in Novo Nordisk’s popular drugs, Wegovy and Ozempic. The new program starts at $149, offering a lower-cost alternative as demand for these types of treatments continues to soar.
As more digital health platforms, such as His & Hers and Sesame, begin offering compounded GLP-1 medications, the competition for affordable options is heating up. Noom CEO Geoff Cook highlighted the company’s mission to expand supply and offer reasonably priced treatments. With Wegovy and Ozempic costing around $1,000 per month before insurance, compounded versions present a much more accessible option, especially for those facing shortages of the brand-name drugs.
Noom’s program, called Noom GLP-1 RX, provides a personalized experience where consumers pay $149 for their first month and $279 for subsequent months as their dosage increases. These compounded medications, produced by an FDA-regulated pharmacy, mimic gut hormones to suppress appetite and regulate blood sugar, making them highly effective for weight loss. However, as the FDA does not evaluate compounded products, it urges consumers to choose branded treatments when available.
What sets Noom apart is its comprehensive approach. In addition to the medication, users gain access to psychology-based tools, personalized coaching, and fitness programs to support their long-term weight loss goals. Noom also offers a flexible tapering process for those who wish to stop taking the medication, a significant benefit given that GLP-1 drugs are designed for long-term use.
Noom’s approach to weight loss is grounded in helping users achieve sustainable results, even after they stop using the medication. If participants regain weight within 18 months of completing the program, Noom will provide a free year of service or significant discounts on medication. With this holistic strategy, the company aims to foster lasting weight loss outcomes for its users.
With demand for weight loss treatments at an all-time high, Noom’s new offering is poised to be a game-changer in the digital health space, providing a cost-effective and supportive option for those looking to take control of their health.
